𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer

✍ Scribed by K. Dredge; J. A. Kink; R. M. Johnson; I. Bytheway; L. J. Marton


Publisher
Springer
Year
2009
Tongue
English
Weight
294 KB
Volume
65
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Activity of the histone deacetylase inhi
✍ Xiaozhong Qian; Gulshan Ara; Evan Mills; William J. LaRochelle; Henri S. Lichens 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 751 KB

## Abstract Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer agents. In the current investigation, we examined the activity of the HDACi belinostat in preclinical models of prostate cancer. __In vitro__ proliferation assays demonstrated that belinostat potently i

The antitumor activity of NK012, an SN-3
✍ Hirotsugu Kenmotsu; Masahiro Yasunaga; Koichi Goto; Tatsuya Nagano; Jun-ichiro K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 974 KB

## Abstract ## BACKGROUND: It has been demonstrated that NK012, a novel 7‐ethyl‐10‐hydroxycamptothecin (SN‐38)‐incorporating polymeric micelle, exerts significantly more potent antitumor activity against various human tumor xenografts than irinotecan (CPT‐11) (a water‐soluble prodrug of SN‐38). Co

Antitumor activity of mifepristone in th
✍ El Etreby, M. Fathy; Liang, Yayun; Johnson, Maribeth H.; Lewis, Ronald W. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

## BACKGROUND. Antiprogestins are a promising new class of mammary tumor inhibitors with a unique mechanism of action. Previously published results also suggest a tumorinhibitory effect of antiprogestins in prostate cancer models. The objective of the present studies was to determine whether androg

Preconditioning chemotherapy with paclit
✍ Xiang Huang; Guichun Huang; Haizhu Song; Longbang Chen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 718 KB

## Abstract Adoptive cell therapy involving the use of __ex vivo__ generated cytokine‐induced killer cells (CIKs) provides a promising approach to immunotherapy. However, the therapeutic activity of CIKs is limited by the immunosuppressive factors active in the host. It has become increasingly appa